Advertisement
Screener

GALECTIN THERAPEUTICS INC. (GALT) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised

2.8 / 5 stars · 68/120 Roast Me

GALECTIN THERAPEUTICS INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised

GALECTIN THERAPEUTICS INC. (GALT) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised of 576.73 thousand shares for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-18.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised · last filed 2015-03-18

  • GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2014-12-31 was 0.00 shares.
  • GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2014-09-30 was 0.00 shares.
  • GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2014-06-30 was 47.08K shares.
  • GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2014-03-31 was 529.65K shares.
  • GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2014 was 576.73K shares, a 1053.47% increase from fiscal 2013.
  • GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2013 was 50.00K shares.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 12 month
2014-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-18
0.00 shares
derived: sum of 2 quarters · filed 2015-03-18
47.08K shares
derived: sum of 3 quarters · filed 2015-03-18
576.73K shares
10-K · filed 2015-03-18
2014-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10
47.08K shares
derived: sum of 2 quarters · filed 2014-11-10
576.73K shares
10-Q · filed 2014-11-10
2014-06-3047.08K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07
576.73K shares
10-Q · filed 2014-08-07
2014-03-31529.65K shares
10-Q · filed 2014-05-13
2013-12-3150.00K shares
10-K · filed 2015-03-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
Turn Therapeutics Inc. (TTRX)United States$0.397B-25.68
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
Rezolute, Inc. (RZLT)United States$0.382B-6.45
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63